Welcome to our dedicated page for Colgate Palmolive Co SEC filings (Ticker: CL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Colgate-Palmolive Company (NYSE: CL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings provide detailed information on Colgate-Palmolive’s Oral Care, Personal Care, Home Care and Pet Nutrition businesses, its financial performance and its capital structure.
Colgate-Palmolive’s 8-K filings illustrate how the company uses SEC reports to communicate material events. For example, an 8-K dated November 10, 2025 describes the execution of an underwriting agreement and the issuance of €600,000,000 of 3.250% Senior Notes due 2035 under an automatic shelf registration statement. Other 8-Ks furnish quarterly earnings press releases and explain multi-year productivity initiatives, such as the Strategic Growth and Productivity Program designed to support the company’s 2030 strategy by aligning its organizational structure, optimizing its global supply chain and streamlining overhead.
Filings also list Colgate-Palmolive’s securities registered under Section 12(b) of the Exchange Act, including its common stock (ticker CL) and various series of notes traded on the New York Stock Exchange. Through proxy statements and other periodic reports, investors can review topics such as segment reporting, non-GAAP financial measures like Base Business and organic sales growth, and risk factor disclosures.
On Stock Titan, these SEC documents are updated from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in capital allocation, new debt offerings, productivity program charges or revisions to guidance. Users can quickly scan filings for material information while retaining access to the complete original documents for deeper analysis.
Colgate-Palmolive reported a planned sale of 45,568 shares of its common stock under a Rule 144 notice, with an aggregate market value of $4,279,497.44. The shares are to be sold through Merrill Lynch on the NYSE around 02/04/2026.
The securities were acquired through vesting of performance share unit awards from Colgate-Palmolive in February and September 2024, granted as part of the issuer’s equity compensation plan.
Colgate-Palmolive common stock is being prepared for sale under Rule 144 following an option exercise. A holder plans to sell 97,843 shares of Colgate-Palmolive common stock through Merrill Lynch on the NYSE, with an aggregate market value of $9,223,283.80.
The shares were acquired on 02/04/2026 via an exercise of employee stock options in a broker-assisted cashless transaction, with payment made the same day. Colgate-Palmolive had 806,064,942 shares of common stock outstanding, providing context for the size of this planned sale under Rule 144.
Colgate-Palmolive Company filed a current report to furnish a press release announcing its earnings for the quarter and year ended December 31, 2025. The press release, dated January 30, 2026, is attached as Exhibit 99 and provides the company’s detailed financial results.
The earnings information is provided under Item 2.02 as furnished, not filed, which limits its use under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Colgate-Palmolive Company director reports stock acquisition under compensation plan
A director of Colgate-Palmolive Company reported acquiring 238 shares of common stock on 01/02/2026 at a price of $78.66 per share. The filing notes this represents a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors.
Following this transaction, the director beneficially owns 5,313 shares of Colgate-Palmolive common stock directly and 36 shares indirectly through a family trust.
Colgate-Palmolive Company director reports a small equity transaction. A board member acquired 333 shares of Colgate-Palmolive common stock on 01/02/2026 at a price of $78.66 per share, according to a Form 4 filing. After this transaction, the director beneficially owns 39,648 shares held directly.
The filing explains that the transaction reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the company’s Deferred Compensation Plan for Non-Employee Directors. The form is signed by an attorney-in-fact on 01/06/2026, indicating the report was made on the director’s behalf.
Colgate-Palmolive Company director reports deferred stock award
A director of Colgate-Palmolive Company reported acquiring 301 shares of common stock on 01/02/2026 at a price of $78.66 per share. According to the footnote, this reflects a portion of the director’s annual cash retainer that was deferred into a stock unit account under the Deferred Compensation Plan for Non-Employee Directors, rather than a market purchase for cash.
Following this transaction, the director beneficially owns 37,195 shares directly and 4,719 shares indirectly through a trust. The filing confirms the individual’s status as a director and that the report is filed for one reporting person.
Colgate-Palmolive Company Chairman, President & CEO and director reported a routine tax-related share withholding. On 12/03/2025, the executive disposed of 1,307 shares of common stock at $78.2 per share, coded as an "F" transaction, meaning shares were withheld to cover Medicare and income tax owed on previously granted restricted stock units. The executive continues to hold those restricted stock units, reduced only by the shares used for required tax withholding.
After this transaction, the executive beneficially owns 338,756 shares directly. Additional indirect holdings include 53,923 shares through the issuer's 401(k) plan trustee, 52,000 shares through a spouse trust, and 335 shares through another trust.
Colgate-Palmolive Company officer reports small share withholding for taxes. A company officer serving as COO, Eur., APac, Afr Eur, Skin reported a Form 4 transaction involving Colgate-Palmolive common stock. On 12/03/2025, 221 shares of common stock were disposed of at $78.2 per share, coded as transaction type F, which represents shares withheld to cover Medicare and income tax on previously granted restricted stock units under the company’s incentive compensation plan.
After this tax withholding, the officer beneficially owns 10,415 shares directly, 4,538 shares indirectly through the issuer's 401(k) plan trustee, and 60,745 shares indirectly through a trust. The filing notes that the officer continues to hold the original restricted stock units granted, reduced only by the amount required for this tax withholding.
Colgate-Palmolive Company’s Chief Financial Officer, reported on a Form 4 that shares of company stock were withheld to cover taxes on previously granted restricted stock units. On 12/03/2025, 385 shares of common stock were disposed of at a price of $78.2 per share through tax withholding, coded as transaction type "F," which indicates payment of tax liability from equity awards.
After this transaction, the officer beneficially owns 55,310 shares of Colgate-Palmolive common stock directly, and an additional 326 shares indirectly through the issuer’s 401(k) plan trustee. The filing clarifies that the underlying restricted stock units remain held by the officer, reduced only by the amount required for Medicare and income tax withholding.
Colgate-Palmolive Company executive Kristine Hutchinson, EVP and Controller, reported a small tax-related stock transaction. On 12/03/2025, 41 shares of Colgate-Palmolive common stock were disposed of at $78.2 per share under transaction code "F," which indicates shares were withheld to cover taxes on previously granted restricted stock units.
After this transaction, Hutchinson beneficially owns 11,879 shares of Colgate-Palmolive common stock directly and 8,497 shares indirectly through the issuer's 401(k) plan trustee. The explanation notes that she continues to hold the original restricted stock units, reduced only by the number of shares withheld to satisfy Medicare and income tax obligations.